Enter assignee name

% Expired Patents = 100.0

EPO Patents = 1

Forward Citations = 188

Loading Chart...

9 inventors (with patents filed for the assignee):

Mark E Davis (9 out of 137 patents)

Jianjun Cheng (7 out of 23 patents)

Suzie Hwang Pun (4 out of 7 patents)

4. Nathalie C Bellocq (4 out of 7 patents)

5. Hector Gonzalez (4 out of 11 patents)

6. Kay T Khin (3 out of 15 patents)

7. Jeremy D Heidel (2 out of 5 patents)

8. John J Rossi (1 out of 102 patents)

9. Joanna Yi-Ching Liu (1 out of 1 patent)

10. John J Roosi (0 patent)

9 patents: Sort by Forward Citations

1. 8404662 - Cyclodextrin-based polymers for therapeutics delivery (2013-03-26),

2. 8399431 - Cyclodextrin-based polymers for therapeutics delivery (2013-03-19),

3. 8389499 - Cyclodextrin-based polymers for therapeutics delivery (2013-03-05),

4. 8277846 - Complexing agents for compositions containing inclusion complexes (2012-10-02),

5. 8114983 - Compositions and use of EPAS1 inhibitors (2012-02-14),

6. 8092833 - Compositions containing inclusion complexes (2012-01-10),

7. 7968123 - Complexing agents for compositions containing inclusion complexes (2011-06-28),

8. 7807198 - Compositions containing inclusion complexes (2010-10-05),

9. 7427605 - Inhibitors of ribonucleotide reductase subunit 2 and uses thereof (2008-09-23),

Calando Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel targeted therapies for the treatment of cancer. Using its proprietary RNA interference (RNAi) technology, Calando is dedicated to delivering personalized medicine solutions that improve patient outcomes and quality of life. With a strong pipeline of innovative oncology products, Calando is committed to advancing the field of precision medicine and revolutionizing cancer treatment.

This text is generated by artificial intelligence and may not be accurate.